

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/019998 A3

(51) International Patent Classification⁷: A61K 31/135,
A61P 43/00

model), SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/22621

(22) International Filing Date: 24 August 2001 (24.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/231,065 8 September 2000 (08.09.2000) US

(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BREIER, Alan
[US/US]; 11998 Woods Bay Court, Carmel, IN 46033
(US). HEIMAN, Mark, Louis [US/US]; 7523 Brookview
Circle, Indianapolis, IN 46250 (US). LEANDER, John,
David [US/US]; 8127 Groton Lane, Indianapolis, IN
46260 (US).

(74) Agents: LENTZ, Nelsen, L. et al.; Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE, DK
(utility model), DK, DM, DZ, EC, EE (utility model), EE,
ES, FI (utility model), FI, GB, GD, GE, GI, GM, II, IR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report

(88) Date of publication of the international search report:
23 January 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A METHOD OF TREATING WEIGHT GAIN ASSOCIATED WITH ATYPICAL ANTIPSYCHOTIC USE

(57) Abstract: A method of treating weight gain associated with atypical antipsychotic use which comprises administering to a mammal in need thereof a therapeutically effective amount of N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutylamine hydrochloride.



WO 02/019998 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PC17US 01/22621

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/135 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols).

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BLACKBURN G.L. ET AL: "Weight gain and antipsychotic medication." JOURNAL OF CLINICAL PSYCHIATRY, (2000) 61/SUPPL. 8 (36-42). , XP008005169 page 37, right-hand column, paragraph 3 -page 38, left-hand column, paragraph 1 page 38, right-hand column, paragraphs 2,3 page 39, right-hand column, paragraph 4 — -/-</p>	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

23 July 2002

Date of mailing of the international search report

29/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bazzanini, R

INTERNATIONAL SEARCH REPORT

Inte - nal Application No

PC1/US 01/22621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GREENBERG ISAAC ET AL: "Nonpharmacologic and pharmacologic management of weight gain." JOURNAL OF CLINICAL PSYCHIATRY, vol. 60, no. SUPPL. 21, 1999, pages 31-36, XP008005348 ISSN: 0160-6689 page 31, left-hand column, paragraph 1 page 33, left-hand column, paragraph 2 page 34, right-hand column, paragraphs 2-4 page 35, left-hand column, paragraph 3</p>	1-8, 11-19
P,X	<p>WO 00 56313 A (KNOLL PHARMACEUTICAL COMPANY) 28 September 2000 (2000-09-28) cited in the application page 1, line 4-15,24,25 page 3, line 15-19 page 4, line 14,15 page 7, line 12-21 page 8, line 4-14 table 1 claims 1-20</p>	1-21
P,X	<p>KURZTHALER I. ET AL: "The clinical implications of weight gain in schizophrenia." JOURNAL OF CLINICAL PSYCHIATRY, (2001) 62/SUPPL. 7 (32-37). , XP008005160 page 32, left-hand column, paragraph 1 -right-hand column, paragraph 1 page 33, right-hand column, paragraph 2 page 36, right-hand column, paragraph 2</p>	1-21
P,X	<p>CASEY D.E. ET AL: "The pharmacology of weight gain with antipsychotics." JOURNAL OF CLINICAL PSYCHIATRY, (2001) 62/SUPPL. 7 (4-10). , XP008005168 page 6, left-hand column, paragraph 4 page 6, right-hand column, paragraphs 3-5 page 7, left-hand column, paragraph 2 page 7, right-hand column, paragraph 2 -page 8, left-hand column, paragraph 1 tables 1,2 page 8, right-hand column, paragraph 2 -page 9, left-hand column, paragraph 3</p>	1-21

-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/22621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	ALLISON D.B. ET AL: "Antipsychotic -induced weight gain: A review of the literature." JOURNAL OF CLINICAL PSYCHIATRY, (2001) 62/SUPPL. 7 (22-31). , XP008005159 page 24, right-hand column, paragraph 2 page 28, column 3, paragraph 2	1-21
A	US 5 436 272 A (SCHEINBAUM MONTE L) 25 July 1995 (1995-07-25) column 1, line 28-40 column 2, line 45-61 claims 1-8	1-21
A	US 5 736 541 A (HENDRIKSEN BARRY ARNOLD ET AL) 7 April 1998 (1998-04-07) column 1, line 17-34	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/22621

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-8,11-19 relate to a method of treating weight gain associated to the use of compounds, which are defined by reference to a desirable characteristic or property, namely atypical antipsychotics. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products (i.e. olanzapine, risperidone, sertindole, quetiapine, ziprasidone, clozapine). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds responsible of the weight gain by reference to their pharmacological profile. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products mentioned in claim 9,21 and in the description at page 3, lines 21-24, namely olanzapine, risperidone, sertindole, quetiapine, ziprasidone, clozapine.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22621

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0056313	A	28-09-2000	AU 3757800 A	09-10-2000
			BR 0009159 A	26-12-2001
			CN 1353603 T	12-06-2002
			EP 1162965 A1	19-12-2001
			NO 20014480 A	02-11-2001
			NZ 514009 A	28-09-2001
			TR 200102695 T2	21-01-2002
			WO 0056313 A1	28-09-2000
			US 6376552 B1	23-04-2002
US 5436272	A	25-07-1995	AT 94385 T	15-10-1993
			AU 633529 B2	04-02-1993
			AU 4620789 A	26-06-1990
			CA 2003524 A1	29-05-1990
			DE 68909219 D1	21-10-1993
			DE 68909219 T2	13-01-1994
			DK 177690 A	13-09-1990
			EP 0397831 A1	22-11-1990
			WO 9006110 A1	14-06-1990
			HK 1006002 A1	05-02-1999
			IE 61928 B	30-11-1994
			IL 92406 A	31-07-1995
			JP 6102622 B	14-12-1994
			JP 2503682 T	01-11-1990
			KR 164435 B1	15-01-1999
			LU 90866 A9	18-02-2002
			PH 26677 A	15-09-1992
			ZA 8909058 A	29-08-1990
US 5736541	A	07-04-1998	AP 828 A	28-04-2000
			AT 406771 B	25-08-2000
			AT 902196 A	15-01-2000
			AT 197711 T	15-12-2000
			AT 204280 T	15-09-2001
			AU 5257896 A	16-10-1996
			AU 706471 B2	17-06-1999
			AU 5427996 A	16-10-1996
			BG 62619 B1	31-03-2000
			BG 101900 A	31-03-1999
			BR 9607790 A	07-07-1998
			CA 2214005 A1	03-10-1996
			CH 690579 A5	31-10-2000
			CN 1179160 A , B	15-04-1998
			CZ 9703000 A3	17-12-1997
			DE 19681286 T0	02-04-1998
			DE 69611003 D1	28-12-2000
			DE 69611003 T2	10-05-2001
			DE 69614426 D1	20-09-2001
			DE 69614426 T2	23-05-2002
			DK 108997 A	12-11-1997
			DK 733634 T3	11-12-2000
			DK 733635 T3	08-10-2001
			EE 9700232 A	15-04-1998
			EP 1095941 A1	02-05-2001
			EP 0733634 A1	25-09-1996
			EP 0733635 A1	25-09-1996
			ES 2151991 T3	16-01-2001
			ES 2159346 T3	01-10-2001

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22621

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5736541	A	FI 973750 A	22-09-1997
		GB 2313835 A ,B	10-12-1997
		HU 9802824 A2	28-06-1999
		IL 117613 A	16-07-2000
		JP 11502535 T	02-03-1999
		LT 97148 A ,B	26-01-1998
		LU 90096 A1	22-07-1997
		LV 12018 A	20-04-1998
		LV 12018 B	20-09-1998
		NO 974365 A	22-09-1997
		NZ 306110 A	24-09-1998
		PL 322501 A1	02-02-1998
		PT 733634 T	30-04-2001
		PT 733635 T	28-12-2001
		SE 9703205 A	05-09-1997
		SI 9620040 A ,B	30-06-1998
		SI 733634 T1	30-06-2001
		SI 733635 T1	30-06-2002
		SK 121897 A3	04-03-1998